Long-Acting Inhaler May Help in Early Stage COPD, Too
WEDNESDAY, Sept. 6, 2017 -- The inhaler medication Spiriva (tiotropium bromide) may help slow the progression of COPD if given in the early stages of the disease, a new study suggests.
Researchers found that the drug helped patients preserve more... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2017 Category: General Medicine Source Type: news
Pulmatrix licenses inhaled COPD drug to Vectura
Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura.
The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix licenses inhaled COPD drug to Vectura appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - August 22, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news
Tiotropium Add-on Tx Improved Lung Function in Kids with Asthma
(MedPage Today) -- Disease phenotype had no impact on treatment (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - May 24, 2017 Category: Allergy & Immunology Source Type: news
Spiriva Respimat improves breathing in asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 23, 2017 Category: Research Source Type: news
Single Inhaler Triple Therapy Effective for COPD Single Inhaler Triple Therapy Effective for COPD
A single inhaler triple therapy provides clinical benefits superior to those of the muscarinic antagonist tiotropium alone in patients with symptomatic chronic obstructive pulmonary disease (COPD), according to the TRINITY trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 20, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide
Glenmark Pharmaceuticals said today that the FDA approved its Investigational New Drug application for a Phase II study of its nebulized tiotropium bromide.
The Mahwah, N.J.-based company plans to enroll 155 patients with mild to moderate chronic obstructive pulmonary disease and evaluate its GSP 304 formulation as a daily maintenance treatment for bronchospasm.
Get the full story at our sister site, Drug Delivery Business News.
The post Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Food & Drug Administration (FDA) Respiratory Wall Street Beat Glenmark Pharmaceuticals Source Type: news
FDA Expands Approval of SPIRIVA(R) RESPIMAT(R) (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., Feb. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance t... Biopharmaceuticals, FDA Boehringer Ingelheim, SPIRIVA, RESPIMAT, tiotropium bromide, Asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2017 Category: Pharmaceuticals Source Type: news
FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., February 16, 2017 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in people age... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 16, 2017 Category: Drugs & Pharmacology Source Type: news
Tiotropium Respimat vs Tiotropium HandiHaler in COPD Tiotropium Respimat vs Tiotropium HandiHaler in COPD
These inhalers provide two options for the delivery of tiotropium in patients with COPD. Find out how they compare.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Olodaterol/tiotropium cost effective for COPD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news
Adding Tiotropium to Teen Asthma Therapy Adding Tiotropium to Teen Asthma Therapy
Once-daily tiotropium improved lung function and was safe and well tolerated when added to inhaled corticosteroid therapy, but would a LABA work just as well?Medscape Pulmonary Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 14, 2016 Category: Allergy & Immunology Tags: Pulmonary Medicine Viewpoint Source Type: news
More Respimat data from Boehringer
Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo.
The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London.
This comes 1 day after results from another clinical trial showed the company’s drug-device Stiolto Respimat aids patients with chronic obstructive pulmonary disease walk for longer periods of time without experiencing shortness breath.
The CanoTinA trial looked to invest...
Source: Mass Device - September 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Boehringer Ingelheim Pharmaceuticals Source Type: news
Tiotropium Respimat < sup > ® < /sup > improved lung function in children with asthma
Tiotropium Respimat® improved lung function in children with asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news
MassDevice.com +5 | The top 5 medtech stories for September 6, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary ...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news
